Wave Life Sciences Ltd. (WVE) Announces Fiscal Q4 and Full-Year 2025 Earnings

Wave Life Sciences Ltd. (NASDAQ:WVE) is one of the best hot stocks under $20 to buy. Wave Life Sciences Ltd. (NASDAQ:WVE) released its fiscal Q4 and full-year 2025 earnings on February 26, reporting that it is on track for INLIGHT clinical data update in 1Q 2026, with fat loss similar to GLP-1 observed at three months and anticipated to continue over time and with higher doses of WVE-007 while preserving muscle mass. The company further stated that planning is underway for the initiation of Phase 2a multidose portion of WVE-007 INLIGHT clinical trial for obesity in individuals with higher BMI and comorbidities in 1H 2026, along with additional trials of WVE-007 as an incretin add-on and as post-incretin maintenance in 2026.

Wave Life Sciences Ltd. (NASDAQ:WVE) reported cash and cash equivalents of $602.1 million as of December 31, 2025, compared to $302.1 million as of December 31, 2024, with the growth in cash year-over-year attributed primarily to financing proceeds along with the receipt of milestone payments and research funding from GSK. The company expects its current cash and cash equivalents to be sufficient to fund operations into fiscal Q3 2028. Revenue recognized in fiscal Q4 was $17.2 million compared to $83.7 million in the prior year quarter, while revenue recognized in 2025 was $42.7 million compared to $108.3 million in 2024.

Wave Life Sciences Ltd. (NASDAQ:WVE) is a clinical-stage biotechnology company that develops and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. PRISM combines a deep understanding of human genetics with chemistry innovation and multiple modalities for scientific discoveries and breakthroughs that treat prevalent and rare disorders. It is developing treatments for obesity and other metabolic disorders, Duchenne muscular dystrophy, Huntington’s disease (HD), and alpha-1 antitrypsin deficiency.

While we acknowledge the potential of WVE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.